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Abstract
Two studies recently reported around 10% of EGFR activating mutations in triple negative breast cancers from
Asian patients. However, we did not find any EGFR activating mutation in a series of 229 breast tumor samples
from European patients. Like in lung cancer, the EGFR mutation profiles seem to be related to the ethnical origin of
patients. This is an important point that should be considered when developing anti-EGFR therapies.
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Commentary
We have read with great interest the study on Epidermal
Growth Factor Receptor (EGFR) mutations in breast car-
cinoma by Ning Lv et al published in Diagnostic Pathol-
ogy [1]. Since in lung cancer the choice of anti-EGFR
therapy is based on the presence of EGFR activating
mutations, and due to the importance to the EGFR path-
way in breast cancer, it is crucial to evaluate the presence
of these mutations in the different subtypes of breast can-
cer. The authors reported that, in their series of 139
breast cancers, two (1.4%) tumors harbored activating
EGFR mutations in exon 19 and 21 of this gene. One
tumor was classified as estrogen receptor (ER) (1/105,
0.8%) positive and the other was a triple negative (TN)
tumor (1/10, 10%). Similarly, in a recent study on 70 TN
breast cancers, which were previously described to often
present an EGFR addiction, Teng et al. found 8 (11.4%)
activating EGFR mutations in exon 19 and 21 [2]. Both
works reported findings that were obtained using tumor
samples from Asian patients. We recently analyzed a ser-
ies of 229 TN tumor samples from European patients
with primary breast cancer and found that none had acti-
vating EGFR mutations [3]. In previous reports concern-
ing smaller series of Caucasians patients, no EGFR
activating mutation was found whatever the subtype of
breast cancer studied [4-6]. Similarly, in a cohort of 58
Japanese patients, Toyama et al failed to find exon 19
and 21 EGFR mutations [7]. These results underline geo-
graphic differences in the presence of EGFR activating
mutations as it was already described for non-small cell
lung cancer [8]. This mutational event, which appears to
be mostly limited to Chinese patients with TN breast
cancer, could be related to ethnic or environmental fac-
tors. However, the question of the origin of the geogra-
phical variations in the occurrence of EGFR mutations in
lung and breast cancers is unresolved.
Interestingly, a case of breast metastasis from a pri-
mary lung cancer that was confirmed by the detection
of the same EGFR mutation has been recently reported
[9]. This observation confirms that the presence of this
mutation is not an obstacle to metastasization/tumor
cell growth in the breast microenvironment. Inversely,
we should not forget that some breast cancer character-
istics, like ER expression and HER2 over-expression,
have been also described in lung cancers [10,11]. Lung
and breast cancer subtypes seem to share some biomar-
kers and thus could respond to the same therapies.
At the time of personalized medicine in oncology, more
than ever, molecular patterns break the limits of classify-
ing tumors according to their localization. Mutation pro-
files have to be analyzed in sub-groups of specific
populations. This is a new and promising challenge for
the design of clinical trials involving targeted therapies.
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